STADA Arzneimittel AG — Earnings Release 2015

Feb 29, 2016

News Details

Ad-hoc | 29 February 2016 13:26

STADA Arzneimittel AG: Development as expected in 2015 under difficult framework conditions – dividend to increase – preliminary outlook for 2016 published

STADA Arzneimittel AG / Key word(s): Preliminary Results

29.02.2016 13:26

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---

Bad Vilbel, February 29, 2016 - The Executive Board of STADA Arzneimittel
AG has today, on February 29, 2016, published the preliminary figures for
financial year 2015, which have not yet been audited. Accordingly, Group
sales is expected to have risen by 3 percent to Euro 2,115.1 million
(previous year: Euro 2,062.2 million) (adjusted for currency and portfolio
effects: +4 percent). Reported EBITDA is expected to have decreased by 10
percent to Euro 377.1 million (previous year: Euro 418.8 million). Adjusted
EBITDA is anticipated to have decreased by 10 percent to Euro 389.4 million
(previous year: Euro 431.9 million). Overall, there were one-time special
effects in the expected amount of Euro 63.1 million before or Euro 55.4
million after taxes. This is anticipated to include a net burden in the
amount of Euro 16.9 million before and after taxes in connection with
currency translation expenses and currency translation income recorded in
the income statement resulting from the fluctuation of the Russian ruble as
well as further significant currencies of the market region CIS/Eastern
Europe. Due to lower impairment losses on intangible assets in comparison
with the previous year following impairment tests, reported net income is
anticipated to have increased by 71 percent to Euro 110.4 million (previous
year: Euro 64.6 million). Adjusted net income is anticipated to have
decreased by 11 percent to Euro 165.8 million (previous year: Euro 186.2
million).

Due to the increased net income reported, the STADA Executive Board
recommends that the Supervisory Board propose to the next Annual General
Meeting on June 9, 2016 a dividend of Euro 0.70 Euro per share for
financial year 2015 (previous year: Euro 0.66). This would represent an
increase in dividend of 6 percent as compared to the previous year. The
resulting total dividend payment of Euro 43.6 million (previous year: Euro
40.0 million) reflects a distribution ratio at approximately 39 percent of
net income reported.

Reported earnings per share are expected to have increased to Euro 1.79
(previous year: Euro 1.07). Adjusted earnings per share are expected to
have decreased to Euro 2.69 (previous year: Euro 3.08).

As of the balance sheet date, net debt is expected to amount to Euro
1,215.7 million (December 31, 2014: Euro 1,327.5 million). In financial
year 2015, the net debt to adjusted EBITDA ratio is expected to amount to
3.1 (previous year: 3.1).

Cash flow from operating activities is expected to have amounted to Euro
311.7 million in financial year 2015 (previous year: Euro 223.8 million).
Free cash flow is anticipated to have amounted to Euro 133.5 million
(previous year: Euro -38.2 million). Free cash flow adjusted for payments
for significant investments or acquisitions and proceeds from significant
disposals is anticipated to have amounted to Euro 212.4 million (previous
year: Euro 157.4 million).

For the preliminary outlook for 2016, the Executive Board currently
anticipates slight growth in Group sales adjusted for currency and
portfolio effects, adjusted EBITDA and adjusted net income. The Executive
Board expects the ratio of net debt excluding further acquisitions to
adjusted EBITDA to be at a level of nearly 3.

In the first quarter of the current financial year, from today's
perspective the Executive Board anticipates more subdued development.

STADA will publish its final figures for financial year 2015 including the
forecast for financial year 2016 on March 23, 2016.

STADA Key Figures

                         2015                 2014                 +/-

Group sales Euro 2,115.1 million Euro 2,062.2 million +3%

EBITDA, reported Euro 377.1 million Euro 418.8 million -10%

EBITDA, adjusted Euro 389.4 million Euro 431.9 million -10%

Net income, reported Euro 110.4 million Euro 64.6 million +71%

Net income, adjusted Euro 165.8 million Euro 186.2 million -11%

Earnings per share Euro 1.79 Euro 1.07 +67%

Earnings per share, adjusted Euro 2.69 Euro 3.08 -13%

STADA adjustments

                                                               2015

Net income, reported Euro
110.4
million

One-time effects

Net burden from currency translation expenses and currency Euro
translation income recorded in the income statement resulting from +16.9
the fluctuation of the Russian ruble as well as further million
significant currencies of the market region CIS/Eastern Europe

Burden from additional scheduled depreciation and other Euro
measurement effects due to purchase price allocations as well as +10.6
significant product acquisitions taking financial year 2013 as million
basis

Burden from value adjustments netted of write-ups on intangible Euro
assets after impairment tests +29.1
million

Net burden from effects from the measurement of derivative Euro
financial instruments and the underlying transactions +2.9
million

Net relief from several extraordinary expenses and income, among Euro
other things, from damage and claim payments made and received, -4.1
tax rate changes in the United Kingdom, successful sale of a million
French branded product company and expenses in connection with
the disposal of the German logistics activities

Total one-time effects Euro
55.4
million

Net income, adjusted Euro
165.8
million

Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2-18 / 61118 Bad
Vilbel - Germany /
Tel.: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail:
ir@stada.de

Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad
Vilbel - Germany /
Tel.: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail:
press@stada.de

Or visit us in the Internet at www.stada.com.

29.02.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard);
Regulated Unofficial Market in Berlin, Hamburg, Hanover,
Munich, Stuttgart; Terminbörse EUREX

End of Announcement DGAP News-Service

---